Prucalopride accepted by NICE

Prucalopride (Resolor) has been recommended by NICE as a possible treatment for women with chronic constipation.

According to the new guidance, women are eligible to receive the 5HT4 agonist on the NHS if:

  • they have tried at least two different types of laxatives at the highest tolerated recommended doses for at least 6 months, without adequate relief
  • invasive treatment of constipation is being considered.

Prucalopride should be prescribed only by a clinician experienced in treating chronic constipation, who has carefully reviewed the woman’s previous laxative use. Treatment should be reviewed after 4 weeks.

Prucalopride was launched in January 2010. Marketing authorisation was granted for use only in women as regulators felt that the drug had not been sufficiently evaluated in men.

View Resolor drug record

Further information: Movetis

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

New antibiotic prescribing guidance issued for pneumonia

New antibiotic prescribing guidance issued for pneumonia

NICE has published antimicrobial prescribing guidelines...

MIMS summary of NICE COPD guidance updated

MIMS summary of NICE COPD guidance updated

Prescribers can now consult the quick-reference MIMS...

Soft-mist inhaler now available as reusable device

Soft-mist inhaler now available as reusable device

Respimat is now available as a reusable inhaler that...

NICE recommends 'innovative' treatment for type I diabetes

NICE recommends 'innovative' treatment for type I diabetes

Dapagliflozin (Forxiga) has been approved for routine...